schliessen

Filtern

 

Bibliotheken

Liposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines

Liposomes containing monophosphoryl lipid A (MPLA) have previously exhibited considerable potency and safety in human trials with a variety of candidate vaccines, including vaccines to malaria, HIV-1 and several different types of cancer. The long history of research and development of MPLA and lipo... Full description

Journal Title: Expert Review of Vaccines 01 June 2012, Vol.11(6), pp.733-744
Main Author: Alving, Carl R
Other Authors: Rao, Mangala , Steers, Nicholas J , Matyas, Gary R , Mayorov, Alexander V
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 1476-0584 ; E-ISSN: 1744-8395 ; DOI: 10.1586/erv.12.35
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: informaworld_s10_1586_erv_12_35
title: Liposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines
format: Article
creator:
  • Alving, Carl R
  • Rao, Mangala
  • Steers, Nicholas J
  • Matyas, Gary R
  • Mayorov, Alexander V
subjects:
  • Adjuvant
  • Adjuvant Mechanisms
  • Adjuvant Systems
  • Data Mining
  • Lipid A
  • Liposomes
  • Monophosphoryl Lipid A
  • Patents and Intellectual Property
  • Peptide Vaccines
  • Biology
ispartof: Expert Review of Vaccines, 01 June 2012, Vol.11(6), pp.733-744
description: Liposomes containing monophosphoryl lipid A (MPLA) have previously exhibited considerable potency and safety in human trials with a variety of candidate vaccines, including vaccines to malaria, HIV-1 and several different types of cancer. The long history of research and development of MPLA and liposomal MPLA as vaccine adjuvants reveals that there are numerous opportunities for creation and development of generic (nonproprietary) adjuvant system formulations with these materials that are not only highly potent and safe, but also readily available as native materials or as synthetic compounds. They are easily manufactured as potentially inexpensive and easy to use adjuvant systems and might be effective even with synthetic peptides as antigens.
language: eng
source:
identifier: ISSN: 1476-0584 ; E-ISSN: 1744-8395 ; DOI: 10.1586/erv.12.35
fulltext: fulltext
issn:
  • 1476-0584
  • 14760584
  • 1744-8395
  • 17448395
url: Link


@attributes
ID715468541
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid10_1586_erv_12_35
sourceidinformaworld_s
recordidTN_informaworld_s10_1586_erv_12_35
sourcesystemOther
dbid
0ABJXJ
1ABLKL
2ADCVX
3AIJEM
4BLEHA
5CCCUG
6TFL
7TFW
pqid1033158041
galeid298907502
ingidftd/erv/2012/00000011/00000006/art00010
display
typearticle
titleLiposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines
creatorAlving, Carl R ; Rao, Mangala ; Steers, Nicholas J ; Matyas, Gary R ; Mayorov, Alexander V
ispartofExpert Review of Vaccines, 01 June 2012, Vol.11(6), pp.733-744
identifier
subjectAdjuvant ; Adjuvant Mechanisms ; Adjuvant Systems ; Data Mining ; Lipid A ; Liposomes ; Monophosphoryl Lipid A ; Patents and Intellectual Property ; Peptide Vaccines ; Biology
descriptionLiposomes containing monophosphoryl lipid A (MPLA) have previously exhibited considerable potency and safety in human trials with a variety of candidate vaccines, including vaccines to malaria, HIV-1 and several different types of cancer. The long history of research and development of MPLA and liposomal MPLA as vaccine adjuvants reveals that there are numerous opportunities for creation and development of generic (nonproprietary) adjuvant system formulations with these materials that are not only highly potent and safe, but also readily available as native materials or as synthetic compounds. They are easily manufactured as potentially inexpensive and easy to use adjuvant systems and might be effective even with synthetic peptides as antigens.
languageeng
source
version10
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
linktorsrc$$Uhttp://www.tandfonline.com/doi/abs/10.1586/erv.12.35$$EView_record_in_Taylor_&_Francis
search
creatorcontrib
0Alving, Carl R
1Rao, Mangala
2Steers, Nicholas J
3Matyas, Gary R
4Mayorov, Alexander V
titleLiposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines
description

Liposomes containing monophosphoryl lipid A (MPLA) have previously exhibited considerable potency and safety in human trials with a variety of candidate vaccines, including vaccines to malaria, HIV-1 and several different types of cancer. The long history of research and development of MPLA and liposomal MPLA as vaccine adjuvants reveals that there are numerous opportunities for creation and development of generic (nonproprietary) adjuvant system formulations with these materials that are not only highly potent and safe, but also readily available as native materials or as synthetic compounds. They are easily manufactured as potentially inexpensive and easy to use adjuvant systems and might be effective even with synthetic peptides as antigens.

subject
0Adjuvant
1Adjuvant Mechanisms
2Adjuvant Systems
3Data Mining
4Lipid A
5Liposomes
6Monophosphoryl Lipid A
7Patents and Intellectual Property
8Peptide Vaccines
9Biology
general
0English
1Taylor & Francis
210.1586/erv.12.35
3Taylor & Francis Online - Journals
4Taylor & Francis (Taylor & Francis Group)
sourceidinformaworld_s
recordidinformaworld_s10_1586_erv_12_35
issn
01476-0584
114760584
21744-8395
317448395
rsrctypearticle
creationdate2012
addtitleExpert Review of Vaccines
searchscope
0informaworld_full
1informaworld2
scope
0informaworld_full
1informaworld2
lsr45$$EView_record_in_Taylor_&_Francis
tmp01Taylor & Francis (Taylor & Francis Group)
tmp02
0ABJXJ
1ABLKL
2ADCVX
3AIJEM
4BLEHA
5CCCUG
6TFL
7TFW
startdate20120601
enddate20120601
lsr40Expert Review of Vaccines, 01 June 2012, Vol.11 (6), pp.733-744
doi10.1586/erv.12.35
citationpf 733 pt 744 vol 11 issue 6
lsr30VSR-Enriched:[pqid, galeid, ingid]
sort
titleLiposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines
authorAlving, Carl R ; Rao, Mangala ; Steers, Nicholas J ; Matyas, Gary R ; Mayorov, Alexander V
creationdate20120601
lso0120120601
facets
frbrgroupid4639685003314328068
frbrtype5
newrecords20190718
languageeng
topic
0Adjuvant
1Adjuvant Mechanisms
2Adjuvant Systems
3Data Mining
4Lipid A
5Liposomes
6Monophosphoryl Lipid A
7Patents and Intellectual Property
8Peptide Vaccines
9Biology
collectionTaylor & Francis Online - Journals
prefilterarticles
rsrctypearticles
creatorcontrib
0Alving, Carl R
1Rao, Mangala
2Steers, Nicholas J
3Matyas, Gary R
4Mayorov, Alexander V
jtitleExpert Review of Vaccines
creationdate2012
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Alving
1Rao
2Steers
3Matyas
4Mayorov
aufirst
0Carl R
1Mangala
2Nicholas J
3Gary R
4Alexander V
auinitC
auinit1C
au
0Alving, Carl R
1Rao, Mangala
2Steers, Nicholas J
3Matyas, Gary R
4Mayorov, Alexander V
atitleLiposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines
jtitleExpert Review of Vaccines
risdate20120601
volume11
issue6
spage733
epage744
pages733-744
issn1476-0584
eissn1744-8395
formatjournal
genrearticle
ristypeJOUR
abstract

Liposomes containing monophosphoryl lipid A (MPLA) have previously exhibited considerable potency and safety in human trials with a variety of candidate vaccines, including vaccines to malaria, HIV-1 and several different types of cancer. The long history of research and development of MPLA and liposomal MPLA as vaccine adjuvants reveals that there are numerous opportunities for creation and development of generic (nonproprietary) adjuvant system formulations with these materials that are not only highly potent and safe, but also readily available as native materials or as synthetic compounds. They are easily manufactured as potentially inexpensive and easy to use adjuvant systems and might be effective even with synthetic peptides as antigens.

pubTaylor & Francis
doi10.1586/erv.12.35
urlhttp://www.tandfonline.com/doi/abs/10.1586/erv.12.35
date2012-06-01